Schizophrenia is not a one-size-fits-all condition, and people often find themselves in a cycle of discontinuing and switching therapies. Studies have shown that approximately 40% of people with schizophrenia do not respond to therapy, and up to 60% experience a partial or inadequate improvement or intolerable side effects during therapy.

The FDA recently approved a new medication for the treatment of schizophrenia in adults, representing the first new class of medicine in more than 30 years. This new treatment option leverages a novel pathway and represents a new mechanistic approach to addressing the symptoms of schizophrenia.

Dr. Gus Alva, a Distinguished Fellow of the American Psychiatry Association will be available to discuss the significance of this new treatment for adults living with schizophrenia and their care partners, and its potential to transform the treatment landscape.

FOR THE FIRST TIME IN 30 YEARS, THE FDA HAS APPROVED THE FIRST DRUG REPRESENTING A NEW CLASS OF MEDICINE FOR THE TREATMENT OF SCHIZOPHRENIA.

ADULTS LIVING WITH SCHIZOPHRENIA HAVE A NEW TREATMENT OPTION TO HELP MANAGE THEIR CONDITION THAT INTRODUCES A FUNDAMENTALLY DIFFERENT APPROACH TO THE TREATMENT OF SCHIZOPHRENIA.

JOINING US NOW WITH MORE INFORMATION IS DR. GUS ALVA,  DISTINGUISHED  LIFETIME FELLOW OF THE AMERICAN PSYCHIATRY ASSOCIATION.

BIO

Dr. Gus Alva is the medical director of ATP clinical research (a premiere private clinical research company specializing in neuropsychiatric investigations). He is an Associate Professor in the Department of Psychiatry and Human Behavior at the University of California, Irvine (UCI). He is a forensic psychiatric consultant for the Orange County Superior Court and a diplomate of the American Board of Psychiatry and Neurology.

Dr. Alva received his medical degree from the Autonomous University of Guadalajara (UAG). Residency training was completed at the University of California, Irvine Medical Center in the Department of Psychiatry and Human Behavior, where he served as chief resident during his final year of residency.

Dr. Alva has served as a principal investigator for the past 10 years conducting investigations in a myriad of neuropsychiatric conditions: Alzheimer’s and other dementias, depression, anxiety disorders, bipolar disorder and psychotic conditions. As a clinician and investigator, Dr Alva’s focus is on the genetics, neuroimaging, and latest treatments available for each aforementioned condition, as well as aspects of ethnicity and their correlation within clinical situations. He has published numerous articles, and presents at both national and international meetings and conferences.

He is the immediate past-president of the Orange County Psychiatric Society. Dr. Alva is also a member of many professional organizations, including the American Medical Association, the Orange County Medical Association, the California Psychiatric Association, the American Board of Forensic Medicine, the American College of Forensic Examiners, the California Hispanic American Medical Association and the International Congress of Geriatric Psychopharmacology.

IMORTANT SAFETY INFORMATION: INDICATION

COBENFY (xanomeline and trospium chloride) is a prescription medicine used to treat schizophrenia in adults.

It is not known if COBENFY is safe and effective in children.

IMPORTANT SAFETY INFORMATION Do not take COBENFY if you:

•        have urinary retention problems that cause your bladder to not empty completely or not empty at all

•        have moderate or severe liver problems (impairment)

•        have gastric retention problems that cause your stomach to empty slowly

•        are allergic to COBENFY, xanomeline, or trospium chloride, or any of the ingredients in COBENFY

•        have an eye problem called untreated narrow-angle glaucoma

Before taking COBENFY, tell your healthcare provider about all of your medical conditions, including if you:

•        have an enlarged prostate, problems passing urine, or a blockage in your urinary bladder

•        have liver problems

•        have or have had gallstones or problems with your bile ducts or pancreas

•        have stomach or intestinal problems, including constipation, ulcerative colitis, slow emptying of your stomach, or myasthenia gravis

•        have an eye condition called narrow-angle glaucoma

•        have kidney problems

•        are pregnant or plan to become pregnant. It is not known if COBENFY may harm your unborn baby. Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with

COBENFY. o               There is a pregnancy exposure registry for women who take COBENFY during pregnancy. The purpose of this registry is to collect information about the health of women exposed to COBENFY and their baby. If you become pregnant during treatment with COBENFY, your

healthcare provider will register you by calling 1-866-961-2388 or online at https://womensmentalhealth.org/research/pregnancyregistry/atypicalantipsychotic/

•        are breastfeeding or plan to breastfeed. It is not known if COBENFY passes into your breast milk or if it can harm your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. Taking COBENFY with certain other medicines may increase your risk of side effects from COBENFY or the other medicine

The post BREAKING NEW GROUND IN SCHIZOPHRENIA TREATMENT appeared first on Good News!.

C. difficile infection (C. diff infection) is a highly contagious bacterial infection that causes half a million illnesses and tens of thousands of deaths in the U.S. each year. Yet, few people know what it is and how it occurs, despite being declared a public health threat by the U.S. Centers for Disease Control and Prevention (CDC).1-3

C. diff infection causes debilitating symptoms such as severe diarrhea, fever, stomach pain, loss of appetite, nausea and colitis.1 This infection can happen to anyone, at any age, and can be contracted in some of the most common places in the community and in hospitals.4-6 When the infection strikes, it can have a devastating impact on everyday life, including taking care of loved ones, going to work regularly and carrying out typical activities. And C. diff infection can come back – known as a recurrence.

Antibiotics – the current standard of care for treatment of C. diff infection – treat the disease but also can be a contributing factor to the cycle of recurrence.1,7 It has been estimated that up to 35% of C. diff infection cases can recur after the initial diagnosis8-11, and after first recurrence up to 65% may develop a subsequent recurrence.11,12

Recently, the FDA approved a first-of-its-kind microbiome-based treatment to prevent recurrent C. diff infection after completing antibiotics for recurrent C. diff infection.

Paul Feuerstadt, M.D., Yale University School of Medicine, will discuss:
• What is C. diff infection and who is vulnerable to contracting it
• Why does this infection recur and what are the consequences of recurrence
• What are the treatment options for recurrent C. diff infection
• How has the newest FDA-approved treatment changed how recurrent C. diff infection may be treated

Patricia, who suffered from recurrent C. diff infection, will share her personal story of her struggle with the infection, how it impacted her life and how she broke the cycle of recurrence.
Footnotes available on request

Courtesy: Ferring Pharmaceuticals
www.REBYOTA.com

Interview is courtesy of Ferring Pharmaceuticals

The post A DEVASTATING DISEASE YOU MAY NEVER HAVE HEARD OF BUT YOU SHOULD KNOW ABOUT: C. DIFFICILE INFECTION appeared first on Good News!.

Dr. Daryl Gioffre is a chiropractor, alkaline lifestyle expert, health coach, certified raw food chef, triathlete, ultra-marathoner, author, and lecturer who uses innovative technology and cutting-edge nutrition to achieve and maintain an OPTIMAL level of health and energy.

Dr. Daryl’s dedication began when his own athletic career was restored through the power of chiropractic following a serious injury he sustained while playing soccer for the United States Under 20 Men’s National Soccer Team. Passionate about his work, Dr. Daryl’s ultimate reward is helping people breakthrough barriers and plateaus in their health that have been holding them back from living a life filled with energy and vitality.

A former sugar addict turned health machine, Dr. Daryl knows firsthand what it takes to overcome adversity and challenges in your health. His approach is one of moderation, not deprivation, and is an inspiration to his patients as he ‘walks the talk’ everyday to higher levels of health, fitness, and energy. His specialty is uncovering the root causes of chronic illness, using a comprehensive yet simple set of steps, making healthy changes more convenient and sustainable.

Dr. Gioffre has been practicing chiropractic for 14 years, and opened the Gioffre Chiropractic Wellness Center on the Upper East Side of Manhattan in 2004. In 2013, Dr. Gioffre founded AlkaMind, with the goal of optimizing individual’s health and energy by simplifying the pursuit of an alkaline lifestyle. AlkaMind’s focus is on the ONE UNIVERSAL CONSTANT regarding health: the more alkaline your body THE BETTER, the more acidic THE WORSE.

Call Dr. Gioffre today to find out how he can help you live your best life!

for more info, go to www.GioffreChiropractic.com

The post Dr. Daryl Gioffre :: Chiropractor of New York appeared first on Good News!.